Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies

ABSTRACT The genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been emerging and circulating in different parts of the world from the beginning of the coronavirus disease (COVID-19) pandemic. Variants are divided into three classes: variant of interest, variant of concern, and variant of high consequence depending on its impact on the transmission, disease severity, diagnostics, vaccines, and therapeutics. The variants of concern include the United Kingdom variant (B.1.1.7), South Africa variant (B.1.351), two related California variants (B.1.427 and B.1.429), and Brazil variant (P.1). These SARS-CoV-2 variants have a direct impact on the available COVID-19 vaccines and immunotherapeutics as they can alter the neutralizing activity of vaccine-elicited antibodies and monoclonal antibodies resulting in mild-to-substantial loss of efficacy. There is a need to establish surveillance systems that can monitor the emergence of novel SARS-CoV-2 variants worldwide.

[1]  D. Bonsall,et al.  Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial , 2021, The Lancet.

[2]  S. Panda,et al.  Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B 1.1.7 variant of SARS-CoV-2 , 2021, Journal of travel medicine.

[3]  M. Mulligan,et al.  B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies , 2021, bioRxiv.

[4]  A. Darby,et al.  Covid-19: variants and vaccination , 2021, BMJ.

[5]  F. Pereira.  SARS-CoV-2 variants lacking ORF8 occurred in farmed mink and pangolin , 2021, Gene.

[6]  S. Madhi,et al.  Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant , 2021, The New England Journal of Medicine.

[7]  Robert J. Fischer,et al.  ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 , 2021, bioRxiv.

[8]  C. Rosset,et al.  Detection of SARS-CoV-2 lineage P.1 in patients from a region with exponentially increasing hospitalization rates in February 2021, Rio Grande do Sul, Southern Brazil , 2021, medRxiv.

[9]  William T. Harvey,et al.  Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.

[10]  L. Danon,et al.  Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study , 2021, BMJ.

[11]  R. Andino,et al.  Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation , 2021, medRxiv.

[12]  D. Ho,et al.  Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization , 2021, bioRxiv.

[13]  M. Beer,et al.  SARS-CoV-2 spike D614G change enhances replication and transmission , 2021, Nature.

[14]  D. Ho,et al.  Emergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York , 2021, medRxiv.

[15]  D. Bonsall,et al.  Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7) , 2021 .

[16]  B. Haynes,et al.  SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines , 2021, bioRxiv.

[17]  D. Ho,et al.  Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 , 2021, bioRxiv.

[18]  B. Graham,et al.  mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants , 2021, bioRxiv.

[19]  Carl A. B. Pearson,et al.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.

[20]  R. Tiwari,et al.  SARS-CoV-2 infection in farmed minks, associated zoonotic concerns, and importance of the One Health approach during the ongoing COVID-19 pandemic , 2020, The veterinary quarterly.

[21]  R. Tiwari,et al.  International travel during the COVID-19 pandemic: implications and risks associated with ‘travel bubbles’ , 2020, Journal of travel medicine.

[22]  Carl A. B. Pearson,et al.  Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant 501Y.V2 , 2022 .